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Abstract 
Pneumococcal conjugate vaccines (PCVs) were developed through chemical coupling of polysaccharide 
capsules of pneumococci to immunogenic carrier proteins and World Health Organization recommends 
inclusion of these vaccines in national immunization programs for children. However, the PCVs implementation 
in developing countries is prevented by the high vaccine manufacturing costs. This issue can be resolved by 
construction of protein based vaccines against pneumococci. We already identified three pneumococcal surface 
proteins including autolysin, zinc binding lipoprotein (ZBL), and plasmid stabilization protein (PSP) as 
appropriate protein candidates for eliciting protection against S. pneumoniae serotype 19F. The protein 
protective antigenicity and the absence of autoimmunity induction were used as selection criteria. However, 
regarding the necessity of the antibody response for protection against pneumococci, analysis of protective B-
cell epitopes of these proteins is required to elucidate their usefulness in new vaccine formulations. In the 
present study, therefore, we aim to identify protective B-cell epitope regions of these proteins via widely used 
bioinformatic tools. Both of the Bepipred and BCPreds programs were used for identification of linear B-cell 
epitopes. The conformational B-cell epitopes were predicted using the CBTope program. The immunoprotective 
abilities of epitopes were evaluated using VaxiJen. We determined the linear B-cell epitope regions, which were 
predicted by both Bepipred and BCPreds and have common amino acids with conformational B-cell epitopes. 
Our results showed that all of the three studied proteins included such protective overlapped linear B-cell 
epitope regions. However, a truncated form of PSP had the greatest number of the protective overlapped B-cell 
epitope regions.  
------------------------------------------------------------------------ 
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Moreover, the most probable protective epitope region resides in this protein and this epitope region is 
completely conserved in PSPs of serotype 19F pneumococcal strains. Therefore, the truncated PSP was an 
appropriate candidate for development of protein based vaccines against S. pneumoniae serotype 19F.   
Keywords: B-cell Epitopes; Pneumococcal serotypes; Pneumococcal vaccines; Streptococcus pneumoniae. 
1. Introduction  
Streptococcus pneumoniae is a major pathogen that causes diseases such as pneumoniae, meningitis and sepsis 
[1]. World Health Organization (WHO) estimated that 476000 annual deaths among children less than 5 years of 
age were caused by pneumococcal infections [2]. S. pneumoniae serotype 19F is among the main pneumococcal 
serotypes that cause most invasive pneumococcal disease in children less than 5 years of age globally [3]. 
Pneumococcal vaccines have been used for protection against pneumococcal infections. The polysaccharide 
capsules of pneumococci are main antigenic components of these vaccines. However, the capsules are poorly 
immunogenic in children and are not able to induce anamnestic antibody responses upon revaccination. In order 
to circumvent these issues, the capsules are chemically conjugated to immunogenic carrier proteins. Therefore, 
the capsules are converted from T-cell independent antigens to T-cell dependent antigens, which enhance 
antibody responses and induce the immune memory. WHO recommends inclusion of pneumococcal conjugate 
vaccines (PCVs) in national immunization programs for children [2]. However, high manufacturing costs of 
PCVs limit their implementation in developing countries [1,2]. Development of protein based vaccines against 
pneumococci offers a more affordable protective strategy against pneumococcal infections. Cell surface proteins 
are key factors in infectious processes of pathogens and have extensively been evaluated as vaccine candidates 
[4,5]. We already identified three pneumococcal surface proteins including autolysin, zinc binding lipoprotein 
(ZBL), and plasmid stabilization protein (PSP) as protein candidates for eliciting protection against S. 
pneumoniae serotype 19F. The candidate selection was based on the protective antigenicity, and the absence of 
autoimmunity induction [6]. Antibody responses are required to protect against pneumococcal infections [7]. 
Thus, analysis of protective B-cell epitopes in the candidates is necessary to evaluate the effectiveness of these 
proteins as new vaccine constituents. Compared with conventional laboratory methods, computational 
approaches offer the ability to undertake rapid and comprehensive epitope assessments for vaccine candidates at 
much lower costs [8]. In the present study, therefore, we analyzed autolysin, ZBL, and PSP via widely used 
bioinformatic tools for identification of immunoprotective B-cell epitope regions. To our knowledge, there is no 
report concerning recognition of B-cell epitope regions of these proteins for the purpose of vaccine development 
against S. pneumoniae serotype 19F.  
 2. Materials and Methods 
The NCBI accession numbers of autolysin, ZBL, and PSP were WP_000405240, WP_000724068, and 
WP_00034749 respectively. PSP was indicated in our previous work [6] as cell wall surface anchor family 
protein under accession number YP_002743140. Conserved domains of proteins were specified using Pfam. 
Protein sequences were submitted to the Bepipred and BCPreds programs for identification of linear B-cell 
epitopes. The immunoprotective abilities of selected B-cell epitopes were evaluated using VaxiJen. A higher 
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VaxiJen score refers to a higher probability for protective ability [9]. The CBTope program was used to predict 
conformational B-cell epitopes using amino acid sequences of the protein.  
COBALT alignment tool was used for the epitope region conservancy analysis in PSPs of serotype 19F 
pneumococcal strains. Accession numbers of PSPs were KKW85405 (S. pneumoniae CU-SPNE1-05), 
KKW83972 (S. pneumoniae CU-SPNE32-06), AFC95386 (S. pneumoniae ST556), and WP_000873519 (S. 
pneumoniae G54). PHD program was used for the secondary structure prediction. SCRATH was used for 
predicting the protein solubility upon overexpression in Escherichia coli. The default settings were applied to all 
the tools used. 
3. Results and Discussion 
3.1. Identification of protective B- cell epitope regions of autolysin 
Antibodies bind specifically to a continuous amino acid sequence of a protein known as the linear B-cell epitope 
or to a folded structure formed by discontinuous amino acids known as the conformational B-cell epitopes. The 
majority of B-cell epitopes are conformational [10]. Nevertheless, the identification of linear B-cell epitopes has 
demonstrated promising results for selection of the vaccine antigens [11,12]. Therefore, in this study, we 
determined both types of the B-cell epitopes in the proteins. Bacterial autolysins are enzymes capable of 
hydrolyzing peptidoglycan and have a major role in concealing this inflammatory molecule from the immune 
system [13].  
Table 1: Protective linear B-cell epitopes of autolysin identified by Bepipred 
Position1 Epitope sequence VaxiJen score 
13 PQVGVQPY 1.3051 
24 HAHSTGNPHSTVQNEADYHWRKDPE 1.0542 
66 PVDNGAWDVGGGWNAETY 0.4215 
135 YCTNNQPNNHSDHVDPYPY 0.5565 
285 QSADGTGW 1.4423 
294 YLKPDGTLADKPEFTVEPD 1.3907 
 
1: amino acid residue number at the epitope beginning is indicated.  
Bepipred and BCPreds are widely used bioinformatic tools for the linear B-cell epitope identification. The 
Simultaneous application of different linear B-cell epitope prediction tools results in greater accuracy of the 
epitope identification. Therefore, we used both of these tools to determine the B-cell epitope regions in 
autolysin. Nine linear B-cell epitopes were identified in the protein using the Bepipred program. VaxiJen results 
indicated that 6 epitopes among them were immunoprotective (Table 1). In addition, BCPreds identified 7 linear 
B-cell epitopes. Considering VaxiJen results, 5 epitopes among them were protective (Table 2). 
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Table 2: Protective linear B-cell epitopes of autolysin identified by BCPreds 
Position1 Epitope sequence Vaxijen score 
12 LPQVGVQPYRQVHAHSTGNP 1.161 
134 EYCTNNQPNNHSDHVDPYPY 0.4469 
221 RKHTDGNWYWFDNSGEMATG 0.6321 
251 FNEEGAMKTGWVKYKDTWYY 0.7268 
283 FIQSADGTGWYYLKPDGTLA 1.0224 
 
1: The amino acid residue number at the epitope beginning is indicated. 
The CBTope program uses the protein amino acid sequence for the prediction of conformational B-cell epitopes. 
Using this program, 8 conformational B-cell epitope regions were identified in the protein (Table 3). The 
epitope regions beginning at the amino acid residue 97 and 172 were exclusively conformational, whereas the 
rest of the conformational B-cell epitope regions overlapped with the identified linear B-cell epitopes. 
Table 3: Conformational B-cell epitope regions of autolysin 
Position 1 No. of epitope residues Epitope region sequence 2 
1 20 MEINVSKLRT DLPQVGVQPYRQ 
36 7 QNEADYH 
97 7 EFMT DYRLYI 
131 22 KTHEYCTNNQPNNHSDHVDPYPYLAKWG 
172 13 LTIETGWQK NDTGYW 
207 31 YYFDSSGYMLADRWRKHTDGNWYWFDNSGEMATGW 
254 21 EGAMKTGWVKYKDTWYYLDAKEGAMVSNAFIQSA 
300 4 TLAD 
 
1: Amino acid residue numbers at the beginning of epitope regions are indicated. 
2: Amino acid residues of conformational B-cell epitopes in each region are shown underlined. 
The linear B-cell epitopes determined by Bepipred and BCPreds were overlapped at three regions, which 
included amino acids common with the conformational B-cell epitopes (Table 4). Regarding the VaxiJen scores, 
the epitope region beginning at the amino acid 283 was the most probable protective linear B-cell epitope region 
of autolysin. 
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Table 4: Protective overlapped linear B-cell epitope regions of autolysin 
Position 1 B-cell epitope region 2,3 VaxiJen score 
12 LPQVGVQPYRQVHAHSTGNP 1.1610 
134 EYCTNNQPNNHSDHVDPYPY 0.4469 
283 FIQSADGTGWYYLKPDGTLADKPEFTVEP 1.2326 
 
1: Amino acid residue numbers at the beginning of epitope regions are indicated. 
2: Amino acids common with the conformational B-cell epitope regions are in italics. 
3: The most probable linear B-cell epitope region is in bold. 
3.2. Identification of protective B- cell epitope regions of ZBL 
ZBL is a lipoprotein, which is involved in the bacterial zinc uptake. The signal peptide of ZBL is cleaved 
between amino acids 18 and 19 [14]. The mature protein obtained following cleavage of the signal peptide was 
used in the B-cell epitope analysis. Fifteen linear B-cell epitopes were identified in the protein using Bepipred. 
Thirteen epitopes among them were immunoprotective as indicated by VaxiJen results (Table 5). Eight linear B-
cell epitopes were recognized in the protein using BCPreds. Considering VaxiJen scores, four epitopes among 
them were protective (Table 6). 
Table 5: Immunoprotective linear B-cell epitopes of mature ZBL identified by Bepipred 
Position1 Epitope sequence VaxiJen  score 
1 CSNQKQADG 2.2763 
26 QVAGDTA 1.3983 
41 GTEPHEYEPSAKAVA 0..6642 
100 GGEEEEGDHDHGEEGHHHEF 2.0596 
168 KAYTEGLSQAKQ 0.5478 
205 GLSPDAEPSAA 0.8943 
247 SKEAGVK 2.3193 
262 SLTEEDTKAGE 2.0618 
287 QTTDQEGPAIEPEKAEDTKTVQNGYFEDAAVK 1.1307 
354 KMTQAEYKAY 0.6471 
365 TKGYQTDV 1.4374 
385 VQGGQSKKY 2.6108 
461 DNWPTYYPDNLSGQEI 1.0051 
1: The amino acid residue number at the epitope start is indicated. 
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In the CBTope program, 11 conformational B-cell epitope regions were recognized in the mature ZBL (Table 
7). The epitope region beginning at the amino acid residue 430 was exclusively conformational. The rest of the 
conformational epitope regions were overlapped with the identified linear B-cell epitopes.  
Table 6:  Immunoprotective linear B-cell epitopes of mature ZBL identified by BCPreds 
Position1 Epitope sequence VaxiJen score 
58 QDADTFVYENENMETWVPKL 0.5112 
99 PGGEEEEGDHDHGEEGHHHE 2.4164 
285 LKQTTDQEGPAIEPEKAEDT 1.4277 
348 KAKLTGKMTQAEYKAYYTKG 0.7859 
 
1: The amino acid residue number at the epitope start is indicated. 
Table 7: Conformational B-cell epitope regions of mature ZBL 
Position1 No. of epitope 
residues 
Epitope region sequence2 
1 13 CSNQKQADGKLNI 
26 12 QVAGDTANVELLIG 
49 20 PSAKAVAKIQDADTFVYENENMETWV 
141 23 LSADYPDKKE TFEKNAAAYIEKLQALDKAYTEGL 
196 7 YGLKQVAISG 
214 6 AARLAELTEYVKKN 
249 8 EAGVKTDVLNPLESLT 
286 40 KQTTDQEGPAIEPEKAEDTKTVQNGYFEDAAVKDRTLSDYAGNWQSVYPF 
369 19 QTDVTKINITDNTMEFVQGGQ 
430 5 QFSDH 
459 20 EMDNWPTYYPDNLSGQEIAQEMLA 
 
1: Amino acid residue numbers at the beginning of epitope regions are indicated. 
2: Amino acid residues of conformational B-cell epitopes in each region are shown underlined.  
The linear B-cell epitopes identified in the mature ZBL by Bepipred and BCPreds were overlapped at two 
regions, which included amino acids common with the identified conformational B-cell epitopes (Table 8). The 
epitope region beginning at the amino acid 285 showed the highest VaxiJen score and was therefore the most 
probable protective linear B-cell epitope region of the protein. 
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Table 8: Overlapped linear B-cell epitope regions of mature ZBL 
Position1 Epitope region2,3 Vaxijen score 
285 LKQTTDQEGPAIEPEKAEDTKTVQNGYFEDAAV 1.0701 
348 KAKLTGKMTQAEYKAYYTKGYQTDV 0.8959 
1: Amino acid residue numbers at the beginning of epitope regions are indicated. 
2: Amino acids common with the conformational B-cell epitope regions are in italics. 
3: The most probable protective B-cell epitope region is in bold. 
3.3. Identification of protective B- cell epitope regions of PSP 
PSP contains an YSIRK type family signal peptide, which is cleaved between the amino acids 36 and 37. 
Moreover, it contains an LPxTG motif beginning at the amino acid residue 658 [6]. We used the truncated PSP 
containing the amino acids 37-657 for the B-cell epitope analysis. The linear B-cell epitope analysis using 
Bepipred showed the presence of 15 linear B- cell epitopes in the protein. VaxiJen results indicated that all of 
the epitopes were protective (Table 9). BCPreds analysis identified 17 linear B-cell epitopes in the truncated 
PSP. Fourteen epitopes among them were protective as indicated by VaxiJen results (Table 10).  
Table 9: Protective linear B-cell epitopes of truncated PSP identified by Bepipred 
Position1 Sequence VaxiJen score 
2 EVVGETSSSKDNM 1.1265 
24 STSLSAEPHSDTLSLD 0.9694 
41 NSSLSTDNNGGVSINQNKPDITND 1.0703 
94 YGAIGDGVNDDRQAIQ 0.7286 
112 IDAAAQGLGGGNVYFP 1.1389 
173 TDDGAQVEWGPTEDISYSGGTID 0.9767 
199 ALNEEGTKAK 2.1738 
290 YALNDDGKKSENVT 1.6011 
309 FGKSDKSGE 3.0686 
328 TLSTQNPS 1.0665 
367 FDKKVKGESVHYRE 1.7546 
444 INNNSKETEQP 1.7294 
509 NANEKEPVIRDSDGN 0.9024 
540 LSDKNEKEKNKEEKQSNSNNVIDSNQKNGEF  
NSSKDNRQMNDKIDNKQDNKTEEV 
1.6322 
599 VGDGRETENHIN 2.1816 
1: The amino acid residue number at the epitope beginning is indicated. 
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Table 10: Protective linear B-cell epitopes of truncated PSP identified by BCPreds 
Position1 Sequence VaxiJen score 
1  NEVVGETSSSKDNMQMNSLL 1.062 
22  STSTSLSAEPHSDTLSLDNN 0.8067 
55  NQNKPDITNDTMMGNISGME 0.7343 
90  NVKDYGAIGDGVNDDRQAIQ 0.499 
113  DAAAQGLGGGNVYFPEGTYL 0.4168 
173  TDDGAQVEWGPTEDISYSGG 0.9974 
217  GAFAIGNSNNVTIKNVTFKD 0.9995 
293  NDDGKKSENVTIQNSYFGKS 1.2743 
364  GNRFDKKVKGESVHYRESGA 1.3528 
439  VTKNVINNNSKETEQPNIEL 1.0637 
511  NEKEPVIRDSDGNFNIVTEN 0.6281 
534  KIVTNNLSDKNEKEKNKEEK 1.6349 
555  SNSNNVIDSNQKNGEFNSSK 0.7679 
585  NKQDNKTEEVNYKIVGDGRE 1.5427 
1: The amino acid residue number at the epitope beginning is indicated. 
CBTope analysis revealed the presence of 10 conformational B-cell epitope regions in the protein (Table 11). 
The epitope region beginning at the amino acid 615 was exclusively conformational. However, the rest of the 
conformational B-cell epitope regions were overlapped with the linear B-cell epitopes.  
Table 11: Conformational B-cell epitope regions of truncated PSP 
Position1 No. of epitope residues Epitope region sequence2 
51 11 GVSINQNKPDIT 
89 4 LNVKD 
126 5 FPEGTYLVK 
187 5 ISYSGGTIDMNGA 
224 13 SNNVTIKNVTFKDSYQGHAIQIAGSKNVLVDNSR 
272 45 IISKESIQIEPLTRKGFPYALNDDGKKSENVTIQNSYFGKSD
KSGELVTAIGTHYQTLSTQNPSNIKIL NNHF 
375 8 SVHYRESGAALVN 
457 27 ELLRVSDNLVVSENSIFGGKEGIVIEDSKGKITVLNNQF 
520 10 SDGNFNIVTENGLYKIV 
587 8 QDNKTEEVNYKIVGDGRE 
615 7 IVDVKQK 
1: Amino acid residue numbers at the beginning of epitope regions are indicated. 
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2: The amino acid residues of conformational B-cell epitopes in each region are shown underlined.  
The linear B-cell epitopes identified in the truncated PSP by Bepipred and BCPreds were overlapped at 8 
regions, which included amino acids common with the identified conformational B-cell epitopes (Table 12). 
Considering VaxiJen scores, the epitope region beginning at the amino acid 534 was the most probable 
protective linear B-cell epitope region of the protein. Moreover, the VaxiJen score of this overlapped B-cell 
epitope region was higher than those identified in autolysin and the mature ZBL. The conservancy of this region 
in PSPs of pneumococcal serotype19F strains was analyzed using the COBALT multiple protein sequences 
alignment tool. The region was fully conserved in the pneumococcal strains. This result indicated that the 
immunological response elicited against this region is protective against serotype 19F pneumococcal strains. 
The secondary structures predicted for the truncated PSP using the PHD program were α helix, extended strand 
and random coil with the predominance of random coil. The overlapped B-cell epitope region beginning at the 
amino acid residue 534 was located in random coil and extended strand. SCRATCH predicted 80% solubility 
for the truncated PSP upon overexpression in E. coli. Therefore, the protein can be recovered from the cellular 
soluble fraction.  
Table 12: Overlapped linear B-cell epitope regions of truncated PSP 
Position1 Epitope sequence2,3 VaxiJen 
score 
41 NSSLSTDNNGGVSINQNKPDITNDTMMGNISGME 0.9445 
112 IDAAAQGLGGGNVYFPEGTYL 0.5299 
173 TDDGAQVEWGPTEDISYSGGTID 0.9767 
290 YALNDDGKKSENVTIQNSYFGKSDKSGE 1.4416 
364 GNRFDKKVKGESVHYRESGA 1.3528 
439 VTKNVINNNSKETEQPNIEL 1.0637 
509 NANEKEPVIRDSDGNFNIVTEN 0.6279 
534 KIVTNNLSDKNEKEKNKEEKSDKNEKEKNKEEKQSNSNNV 
IDSNQKNGEFNSSKDNRQMNDKIDNKQDNKTEEVNYKIVGDGRETENHIN 
 
1.6046 
1: Amino acid residue numbers at the beginning of epitope regions are indicated. 
2: Amino acids common with the conformational B-cell epitope regions are in italics. 
3: The most probable protective B-cell epitope region is in bold. 
4. Conclusions and Recommendations 
Among three proteins including autolysin, the mature ZBL, and the truncated PSP of S. pneumoniae serotype 
19F, the truncated PSP possesses the greatest number of protective overlapped linear B-cell epitope regions, 
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which were predicted by both Bepipred and BCPreds programs and have amino acids common with the protein 
conformational B-cell epitopes. In addition, the overlapped B--cell epitope region with the most probability of 
eliciting protection resides in this protein and this region is fully conserved in PSPs of serotype 19F 
pneumococcal strains. Therefore, the truncated PSP is considered as an appropriate candidate for development 
of protein based vaccines against S. pneumoniae serotype 19F. In future, the protein ability in eliciting 
protection against pneumococci will be assessed experimentally. The limit of this study was the availabilities of 
the PSP amino acid sequences from serotype 19F S. pneumoniae for the analysis of the epitope conservation. 
Therefore, the experimental assessing of the PSP encoding gene presence in serotype 19F S. pneumonia strains 
and obtaining the amino acid sequence are recommended. 
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